The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable

详细信息    查看全文

• 作者：Thanyanan Reungwetwattana^a ; Ying Liang^b ; Viola Zhu^c ; ^d ; Sai-Hong Ignatius Ou^d ; ^{ignatius.ou@uci.edu}
• 关键词：ALK ; anaplastic lymphoma kinase ; CNS ; central nervous system ; EGFR ; epidermal growth factor receptor ; FDA ; food and drug administration ; GCN ; gene copy number ; HGF ; hepatocyte growth factor ; IC50 ; half inhibitory concentration ; IHC ; immunohistochemistry ; mAb ; monoclonal antibody ; METex14 ; MET exon 14 ; METex14+ NSCLC ; METex14 altered NSCLC ; NSCLC ; non-small cell lung cancer ; ORR ; overall response rate ; PD-1 ; programmed cell death protein 1 ; RTK ; receptor tyrosine kinase ; SqCC ; squamous cell carci
• 刊名：Lung Cancer
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：103
• 期：Complete
• 页码：27-37
• 全文大小：1915 K
• 卷排序：103

文摘

METex14 alterations occur in 2–3% of lung cancers. MET TKIs have shown preliminary clinical benefit in patients with METex14+ NSCLC. Targeting of METex14 alterations is expected to lead to the approval of MET TKIs in NSCLC. Drug switching and/or combination therapy may be required to target resistance.